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Meloxicam is a broadly used drug in the therapeutics for the osteoarthritis and rheumatoid arthritis 
treatments in adults, and it is available in the Brazilian market, as tablet and capsule pharmaceutical 
forms. The present work aimed to establish conditions for accomplishment of the dissolution test of 15 
mg meloxicam tablets (A and B test products), compared with the reference product, since there is no 
monograph about dissolution assays for meloxicam in official summaries. To optimize the conditions 
several parameters were tested and, according to obtained results, the use of pH 7.5 phosphate buffer 
(900mL, at 37 ± 0.5ºC) as dissolution medium, paddle method (apparatus 2), stirring speed of the 
dissolution medium at 100 rpm and collect time of 60 minutes were considered satisfactory. The samples 
were quantified by UV spectrophotometric method at 362 nm. The products presented kinetics of first-
order. Dissolution efficiency values were of 83.25, 83.73 and 88.10% for the A, B and reference products, 
respectively. Factors f1 and f2 were calculated and similarity of the tested medicines was demonstrated. 
The dissolution test was validated presenting selectivity, linearity, precision and accuracy within of the 
acceptance criteria.
Uniterms: Meloxicam/dissolution. Dissolution kinetics. Tablet pharmaceutical forms/dissolution test. 
Spectrophotometry.
O meloxicam é fármaco amplamente utilizado na terapêutica para o tratamento de osteoartrite e artrite 
reumatóide em adultos, e encontra-se disponível no mercado brasileiro, sob as formas farmacêuticas 
comprimido e cápsula. O presente trabalho objetivou estabelecer condições para realização do teste 
de dissolução de meloxicam 15 mg na forma farmacêutica comprimido (medicamentos-teste A e B), 
comparado com o medicamento de referência, visto que não há monografia para o ensaio de dissolução 
com meloxicam em compêndios oficiais. Para otimização das condições, diversos parâmetros foram 
testados e de acordo com os resultados obtidos, a utilização de tampão fosfato pH 7,5 (900mL, a 
37 ± 0,5 ºC) como meio de dissolução, aparato 2 (pá), velocidade de agitação do meio de dissolução 
de 100 rpm e tempo de coleta em 60 minutos, foram considerados satisfatórios. As amostras foram 
quantificadas por espectrofotometria na região do ultravioleta, a 362 nm. Os produtos apresentaram 
cinética de primeira ordem. Para a eficiência de dissolução encontraram-se valores de 83,25, 83,73 e 
88,10% para os medicamentos-teste A e B e referência, respectivamente. Os fatores f1 e f2 foram calculados, 
demonstrando haver similaridade entre os medicamentos avaliados. O ensaio de dissolução foi validado 
apresentando seletividade, linearidade, precisão e exatidão dentro dos critérios de aceitação.
Unitermos: Meloxicam/dissolução. Cinética de dissolução. Comprimidos/teste de dissolução. 
Espectrofotometria.
INTRODUCTION
Drug absorption from solid pharmaceutical forms 
following oral administration depends on the stages of 
disintegration, disaggregation, drug release from the 
pharmaceutical form, its dissolution under physiological 
conditions and the permeability through the biological 
membranes (Abdou, 1995). Based on these considerations, 
in vitro dissolution test is a very important stage to predict 
the drug in vivo performance.
The bioavailability, which describes the rate and ex-
tent of active drug that is absorbed, may be altered by any 
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factor that can change the disintegration and dissolution 
drug process (Storpirtis et al., 1999).
Dissolution profile compares the percentage of a 
drug substance dissolved relating to time (Abdou, 1995) 
and represents an alternative to assessment of solid phar-
maceutical forms before clinical tests.
Regarding Biopharmaceutics Classification System 
(BCS), high permeability and low solubility drugs are 
grouped in class II. In this case, the dissolution profile must 
be quite definite and highly reproducible. Drug dissolution 
of this class is the limiting step for drug absorption. The 
appropriate comparison of drug product formulations in this 
category requires multiple point dissolution tests, in order to 
characterize the dissolution profile (Amidon et al., 1995; Bra-
sil, 2004; Galia et al., 1998; Pillai, Dhanikula, Panchagnula, 
2001). Establishment of an in vitro/in vivo correlation and the 
resulting ability to discriminate between formulations with 
different bioavailabilities will be dependent on how well the 
in vitro tests are designed (Dressman et al., 1998).
Meloxicam is a broadly used drug in the therapeutics 
for the osteoarthritis and rheumatoid arthritis treatments in 
adults. It is one of the few drugs considered “preferential” 
COX 2 inhibitors available in the pharmaceutical market, 
since in the last years some potentially selective drugs, 
such as rofecoxibe and valdecoxibe, were removed from 
the market due to the serious harmful effects that they 
might cause (Engelhardt et al., 1995; Food, 2006; Furst, 
Munster, 2003; Insel, 1996; Korolkovas, 2007).
Several pharmaceutical products containing meloxi-
cam are commercialized in the Brazilian market as similar 
drugs in the tablet pharmaceutical form. They are very 
often interchanging with the reference drug product. Melo-
xicam is a yellow solid drug, practically insoluble in water, 
with higher solubility observed in strong bases. It is very 
slightly soluble in methanol. Meloxicam has an apparent 
partition coefficient (log P) app = 0.1 in n-octanol/buffer 
pH 7.4. Meloxicam has pKa values of 1.1 and 4.2. It is, 
therefore, considered a class II drug (Final, 2006).
The aim of the present work was to establish ex-
perimental conditions, to validate the dissolution test for 
15 mg meloxicam in tablet pharmaceutical form and to 
compare the dissolution profiles obtained from different 
commercial products, using dissolution kinetic studies and 
dissolution efficiency methods.
MATERIALS AND METHODS
Pharmaceutical specialties and chemical 
reference substance
Two pharmaceutical specialties, obtained from the 
Brazilian market in tablet pharmaceutical form, claiming 
to contain 15 mg of meloxicam were tested. Two different 
laboratories supplied these products, which were codified 
as test product A (lot 50011, production date: 2005/01, 
expiration date: 2007/01) and test product B (lot 880, pro-
duction date: 2005/05, expiration date: 2008/05). Referen-
ce product Movatec®, 15mg tablets (lot 8222, production 
date: 2006/09, expiration date: 2008/09) and meloxicam 
reference substance (declared content of 99.60% and ex-
piration date: 2007/05) were also used.
Equipments 
The following equipments were used: Electrolab 
dissolution tester (model TDT-08 L) equipped with ei-
ght dissolution vessels; Unique ultrasonic Bath (model 
USC1400); Kern analytical balance (model 410); Nova 
Técnica vacuum filtration system; Shimadzu UV/VIS 
visible spectrophotometer (model 1601 PC); TKA - HPW 
water purifier system and Marconi digital pHmeter (model 
PA 200).
Optimization of dissolution test
To establish the ideal experimental conditions it was 
used, initially, solutions of meloxicam reference substance 
in pH= 6.8 potassium phosphate buffer; pH= 6.8 potassium 
phosphate buffer, containing 0.01% sodium lauryl sulfate 
and pH= 7.5 potassium phosphate buffer. These solutions 
were prepared using the following reagents: potassium 
dihydrogenphosphate anhydrous PA (Vetec); sodium hy-
droxide PA (Vetec) and sodium lauryl sulfate PA (Vetec). 
Later, a spectral scanning was carried out in order to get 
the wavelength to be used in the drug quantification.
The optimized experimental conditions for obtaining 
the dissolution profiles of the A and B test products were 
established by using the reference product and the conditions 
are presented in Table I. The dissolution test was performed 
by removal of 15 mL samples of dissolution medium at 15, 
30, 45, 60, 75, 90 and 105 minutes, followed by dissolution 
medium replacement. The temperature of the dissolution 
medium was maintained at 37 ± 0.5 °C. The concentration 
of dissolved meloxicam in the dissolution vessels, at prede-
termined time intervals, was determined by ultraviolet spec-
trophotometry in wavelength of 362 nm and was obtained by 
comparison with a standard solution of meloxicam reference 
substance containing a known concentration.
Validation
Dissolution test validation was performed accord-
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ing to ANVISA resolution RE nº 899 (Brasil, 2003) and 
AOAC International (1995) requirements, by means of the 
analysis of selectivity, linearity, precision and accuracy 
parameters.
Selectivity was evaluated by means of the analysis 
of the absorption spectra of the meloxicam reference 
standard and placebo tablet samples of the A and B test 
products, respectively. The samples were prepared and 
submitted under the following dissolution test conditions: 
900 mL of pH= 7.5 potassium phosphate buffer as dissolu-
tion medium, temperature of the batch maintained at 37 
± 0.5 °C, paddle apparatus and stirring speed of 100 rpm. 
Aliquots were collected at 60 minutes and then filtered in 
a quantitative filter paper
Linearity was established by means of the construc-
tion of the calibration curve using meloxicam reference 
standard solutions in the concentrations of 9, 11, 13, 15 
e 17 mg/L, prepared in pH= 7.5 potassium phosphate 
buffer.
The precision of the procedure was determined by 
repeated analyses (n=12) for intra-day and intermediate 
precision, respectively, using tablet samples of the A, B 
and reference products containing meloxicam. The sam-
ples of each product were submitted to the dissolution test 
under the same conditions described in the selectivity.
Accuracy was determined by standard addition 
method. Known amounts of the chemical reference sub-
stance were added to the tablet samples of the A, B and 
reference products, respectively, during dissolution test of 
each product for obtaining three concentration levels of the 
calibration curve: 9, 13 e 17 mg/L. Solutions were filtered 
in a quantitative filter paper and then analyzed by the pro-
posed method. The study was carried out in triplicate and 
the percentage recoveries were calculated.
Dissolution parameters 
To study the drug release kinetics a zero-order kine-
tic model by plotting the undissolved drug amount versus 
the time, and the first-order kinetic model by plotting the 
natural logarithm (ln) of the undissolved drug amount 
versus the time were used (El Yazigi, 1981; Nikolic et al., 
1992). The kinetic parameters of the dissolution such as 
the dissolution rate constant (k) and half-life of release 
(t
50%
) were calculated by using equations of a mathema-
tical model that presented most significant correlation 
coefficient. 
Dissolution efficiency (ED%) was calculated by 
using the ratio between the area above the meloxicam 
dissolution curve (ASC) at the time interval between 0 
and 60 minutes and the total area of the rectangle (ATR) 
(described by 100% dissolution in 60 minutes) (Khan, 
1975). The results of ED% values of the tested products 
were submitted to variance analysis (ANOVA). Tukey 
test was used in order to detect the existence of significant 
differences between the averages.
The comparison of the dissolution profiles obtained 
from the A, B and reference products was also carried 
TABLE I - Established conditions for dissolution test optimization of meloxicam reference product in tablet pharmaceutical form
Condition Apparatus Dissolution medium (900mL) Stirring speed (rpm)
I Paddle pH= 6.8 potassium phosphate buffer 50
II Paddle pH= 6.8 potassium phosphate buffer 75
III Paddle pH= 6.8 potassium phosphate buffer 100
IV Basket pH= 6.8 potassium phosphate buffer 50
V Basket PH= 6.8 potassium phosphate buffer 100
VI Paddle pH= 6.8 potassium phosphate buffer + 0.01% sodium lauryl sulfate 50
VII Paddle pH= 6.8 potassium phosphate buffer + 0.01% sodium lauryl sulfate 75
VIII Paddle pH= 6.8 potassium phosphate buffer + 0.01% sodium lauryl sulfate 100
IX Basket pH= 6.8 potassium phosphate buffer + 0.01% sodium lauryl sulfate 50
X Basket pH= 6.8 potassium phosphate buffer + 0.01% sodium lauryl sulfate 100
XI Paddle pH= 7.5 potassium phosphate buffer 50
XII Paddle pH= 7.5 potassium phosphate buffer 75
XIII Paddle pH= 7.5 potassium phosphate buffer 100
XIV Basket pH= 7.5 potassium phosphate buffer 50
XV Basket pH= 7.5 potassium phosphate buffer 100
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out by means of the determination of the f1 and f2 factors 
(difference factor and similarity factor). The equivalence 
between two profiles is observed when f1 values are betwe-
en 0 and 15 and f2 values are between 50 and 100 (Brasil, 
2004; Moore, Flanner, 1996).
RESULTS AND DISCUSSION
The spectral profiles of meloxicam reference stan-
dard in pH = 6.8 potassium phosphate buffer, pH = 6.8 
potassium phosphate buffer with 0.01% sodium lauryl 
sulfate and pH = 7.5 potassium phosphate buffer sho-
wed maximum drug absorption wavelength at 362 nm. 
Therefore, this wavelength was used for the meloxicam 
quantification throughout the study.
Definition of the appropriate parameters for me-
loxicam tablets dissolution test was made by using the 
reference product (Table I). Different conditions were 
involved such as: dissolution medium composition, use of 
paddle and basket apparatuses and stirring speeds of 50, 
75 and 100 rpm. The results of the studies demonstrated 
that when phosphate buffer, pH = 6.8 or this medium with 
0.01% sodium lauryl sulfate were employed as dissolution 
medium, paddle or basket as apparatus at the stirring speed 
of 50, 75 or 100 rpm, the tablet dissolution was incomplete, 
with release percentage lower than 85% within 90 minutes, 
therefore, not satisfying the minimum requirements esta-
blished by ANVISA (Brasil, 2004). On the other hand, the 
use of pH = 7.5 potassium phosphate buffer as dissolution 
medium and paddle as apparatus at the stirring speed of 
100 rpm yielded a satisfactory dissolution of the drug in 
the first 60 minutes of the test, with drug release higher 
than 85% (Figure 1).
The results obtained from the matrix of the Table I, 
were optimized by means of the application of the Pareto 
analysis. The variables phosphate buffer pH = 6.8, rota-
tion speed of dissolution medium at 50 rpm and basket as 
apparatus were defined as the low level parameters. The 
variables phosphate buffer pH = 7.5, rotation speed of 
dissolution medium at 100 rpm and paddle as apparatus 
were defined as the high level parameters.
Through combinatorial analysis, using the Pareto 
analysis at a 95.0% confidence level, it was possible to 
verify that optimal conditions are obtained with the use 
of pH = 7.5 phosphate buffer as dissolution medium, 
paddle as apparatus and dissolution medium rotation 
speed at 100 rpm. The interactions between variables 
are not statistically significant. Table II shows the levels 
used for accomplishment of the experimental design in a 
24 factorial design for application of the Pareto analysis. 
Figure 2 shows the Pareto chart used for the stablishment 
of the best conditions for accomplishment of dissolution 
profiles of meloxicam tablets.
FIGURE 1- Dissolution profiles of 15 mg meloxicam tablets 
(reference product) in pH = 7.5 potassium phosphate buffer at 
37 ± 0.5°C, using different apparatuses and rotation speeds.
TABLE II – Definition of the experimental levels of the variables 
used in the experimental design for 15 mg meloxicam tablets, 
reference product
Variable Lower level Upper level
Apparatus Basket Paddle
Dissolution 
medium
Phosphate buffer 
pH = 6.8
Phosphate buffer 
pH = 7.5
Rotation speed 
(rpm)
50 100
Time (min) 45 60
FIGURE 2- Pareto chart used for stablishment of the optimal 
conditions for accomplishment of dissolution profiles of 15 mg 
meloxicam tablets.
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For validation of dissolution test it was verified, 
by the analysis of absorption spectra of the placebo ta-
blet samples of products tests A and B, respectively, that 
formulation excipients did not interfere in the absorption 
spectra of the chemical reference substance.
Linearity was obtained in the concentration range 
09-17 mg/L, with a correlation coefficient (r) of 0.9995 
(y= 0.0457x + 0.0371). The estimation of relative standard 
deviation between determinations was smaller than 2%, 
showing linear correlation between drug concentration 
and UV absorption.
Precision, evaluated under established conditions 
of the dissolution test, was determined by the relative 
standard deviation. For Intra-day precision, the overall 
relative standard deviations observed were 0.63% (n=12), 
0.68% (n=12) and 0.72 % (n=12) for the A, B and referen-
ce products, respectively. For intermediate precision, the 
overall relative standard deviation observed were 0.95% 
(n=12), 1.20 % (n=12), e 0.89 % (n=12) for the A, B and 
reference products, respectively. These experimental 
results showed the good precision of the dissolution test 
when it is performed on the same and at different days. 
Relative standard deviations lower than or equal to 5% are 
considered acceptable (Brasil, 2003). 
Accuracy was performed by standard addition me-
thod and evaluated by the recovery test. Known amounts 
of the meloxicam reference standard were added to the 
samples of the A, B and reference products during disso-
lution test. The mean recovery percentages of 98.09, 97.98 
and 98.22 % for the A, B and reference products, respec-
tively, corroborating appropriate recovery. According to 
Marques, Brown (2002), values between 95.0-105.0 % 
are satisfactory.
Dissolution profiles are presented in Figure 3. The 
test products A and B showed homogeneous formulations, 
differing from the behavior of the reference product in the 
first 30 minutes. However, the kinetic parameters deter-
mination is important because they allow the comparative 
analysis of the in vitro behavior between the analyzed 
products. The analysis of variance (ANOVA) revealed a 
statistical difference (p<0.05) between the products. The 
comparison between the optimized dissolution profiles 
was carried out using Tukey test, which demonstrated, 
with a level of significance of 5%, a higher release percent 
for the reference product.
The study of drug release kinetics using the zero-
order and first-order kinetic models was performed. By 
means of the linearization of dissolution profiles the 
respective correlation coefficients (r) were obtained. The 
kinetic model considered more appropriate (the one which 
presented higher value of correlation coefficient) was the 
first-order model for all products (Table III). A first-order 
process of drug particle liberation is expected for conven-
tional solid pharmaceutical forms (Ishi et al., 1996). 
The kinetic parameters of the dissolution test such 
as the dissolution rate constant (k) and half-life of relea-
se (t
50%
) were calculated by using the first-order kinetic 
model. Although the k values cannot be used for direct 
comparison of the profiles, its importance is related to the 
half-life of release (t
50%
) calculation. Half-life of release 
(t
50%
) is of paramount importance because it establishes the 
time to promote the dissolution of 50% of the drug. The 
results indicated differentiated dissolution profiles for the 
analyzed products in the first 20 minutes. Therefore, the 
values of the half-life of the released product (t
50%
) shown 
in Table IV demonstrate a good drug release performance 
for the analyzed products. 
Dissolution efficiency (ED%) also allows the com-
parison of drug dissolution profiles (Khan, 1975). (ED%) 
is related with the real amount of drug dissolved in the 
dissolution medium and thus, lead to a better prognostic 
FIGURE 3- Dissolution profiles of 15 mg meloxicam tablets 
obtained from A, B and reference products, respectively, 
using pH = 7.5 potassium phosphate buffer at 37 ± 0.5 °C as 
dissolution medium and paddle as apparatus at 100 rpm.
TABLE III – Statistical parameters from regression study using 
zero-order and first-order kinetic models. The parameters were 
obtained from dissolution profiles of the A, B and reference 
products, respectively. Conditions: pH = 7.5 potassium 
phosphate buffer at 37 ± 0.5 °C as dissolution medium, paddle 
as apparatus at 100 rpm
Model Zero-order (r) First-order (r)
Test product A 0.8716 0.8988
Test product B 0.8478 0.9325
Reference product 0.8974 0.9722
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for in vivo performance. (ED%) results are shown in Table 
V. The analysis of variance (ANOVA) revealed a statisti-
cal difference (p<0.05) between the products. Tukey test 
demonstrated that A and B test products presented signifi-
cantly smaller values of ED%, respectively, (p<0.05).
The f1 and f2 factors were calculated based on li-
terature data (Brasil, 2004; Moore, Flanner, 1996). The 
obtained results showed similarity between dissolution 
profiles of the A, B and reference products. Dissolution 
profile comparison between test product A and reference 
product yield f1 of 8.63 and f2 of 77.54. Dissolution profile 
comparison between test product B and reference product 
yield f1 of 8.44 and f2 of 81.20. All obtained values are 
within the specifications.
CONCLUSIONS 
The optimal conditions for accomplishment of the 
dissolution test for meloxicam tablets were: 900 mL of pH 
7.5 phosphate buffer at 37 ± 0.5 °C as dissolution medium, 
apparatus 2 (paddle) at the stirring speed of 100 rpm and 
collect time in 60 minutes.
The validation showed that the dissolution test is 
appropriate for quantification of meloxicam in tablet phar-
maceutical form for in vitro studies, presenting selectivity, 
linearity, precision and accuracy.
The experimental dissolution profiles of tested pro-
ducts follow first-order kinetics. Based on the dissolution 
kinetic parameters (k, t
50%
 and ED%) it was verified that 
the analyzed products presented dissolution profiles sta-
tistically different regarding the drug release percent of 
the pharmaceutical form. Nevertheless, the f1 and f2 results 
showed similarity between dissolution profiles of the A, B 
and reference products. For definite conclusions about the 
bioavailability and bioequivalence of these products, it is 
necessary the accomplishment of in vivo studies.
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